Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Companies Involved in Therapeutics Development
AbbVie Inc
Beijing Sunbio Biotech Co Ltd
Chengdu Huachuang Biotechnology Co Ltd
Clover Biopharmaceuticals
Galaxy Biotech LLC
i2 Pharmaceuticals Inc
JN Biosciences LLC
Polaris Pharmaceuticals Inc
Shanghai Gebaide Biotechnology Co Ltd
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drug Profiles
ABBV-621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD19L-sTRAIL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dulanermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Agonize TRAIL Receptor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuD-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuYON-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-30000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignt Pleural Effusions (MPE)
Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in Chi for Malignt Ascites
Sep 10, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in Chi for Peritoneal Carcinomatosis
May 30, 2019: AbbVie presents update on ABBV-621 at the 2019 ASCO
May 07, 2019: Clover Biopharmaceuticals receives NMPA approval for SCB-313 (TRAIL-Trimer) to initiate clinical trials in Chi
Jun 18, 2018: Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignt Ascites
Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019
Pipeline by Chengdu Huachuang Biotechnology Co Ltd, H2 2019
Pipeline by Clover Biopharmaceuticals, H2 2019
Pipeline by Galaxy Biotech LLC, H2 2019
Pipeline by i2 Pharmaceuticals Inc, H2 2019
Pipeline by JN Biosciences LLC, H2 2019
Pipeline by Polaris Pharmaceuticals Inc, H2 2019
Pipeline by Shanghai Gebaide Biotechnology Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019